The effects of next generation probiotics on metabolic dysfunction-associated steatotic liver disease: a parallel, double-blind, randomized, placebo-controlled trial

Key Points

• To investigate the impact of next generation probiotics on metabolic dysfunction-associated steatotic liver disease.
• Conducted a randomized controlled trial
• Utilized a double-blind design
• Included a placebo-controlled group
• Measured effects on liver disease and metabolic dysfunction
• Probiotics demonstrated a reduction in liver disease severity
• Improvements were observed in metabolic dysfunction markers